Present the protocol synopsis, trial objectives, and key endpoints.

Investigator Qualification Assessment: Review the investigator’s CV, GCP training, and clinical trial experience.

Staff and Delegation of Duties: Identify key personnel, roles, and assess training documentation.

Facility Tour: Evaluate patient visit flow, IMP storage, lab capabilities, and document archiving.

Regulatory Readiness: Confirm ability to meet IRB/EC submission timelines and documentation requirements.

Technology Assessment: Check availability of internet access, EDC capabilities, and electronic systems support.

Facility and Infrastructure Evaluation:

Use an SQV checklist to evaluate physical and operational readiness, including:

• Private and compliant informed consent area
• Temperature-controlled drug storage with access logs
• Certified laboratory or access to central lab
• Secure area for source documents and regulatory files

These checks ensure GCP and GMP compliance for clinical operations.

Discussion of Study-Specific Requirements:

Use this opportunity to align expectations:

• Enrollment goals and patient pool availability
• Visit schedule, window flexibility, and visit durations
• Inclusion/exclusion criteria feasibility
• Plans for recruitment support and retention strategies

Document Collection and Review:

Collect or confirm availability of the following:

• CVs and medical licenses
• GCP and protocol-specific training records
• IRB registration and SOP acknowledgment forms
• Delegation of Authority logs (draft)

This documentation is critical to site activation and must be reviewed during the SQV.

Assessing Site Motivation and Engagement:

High-performing sites often demonstrate:

• Strong interest in the protocol and therapeutic area
• Proactive staff with prior experience and availability
• Investigator commitment to compliance and timelines

Gauge willingness to adhere to timelines and reporting obligations as part of your qualification decision.

Post-Visit Activities:

Immediately after the SQV, the CRA or project team should:

1. Complete a detailed SQV report and site assessment form
2. Document recommendations regarding site selection
3. Follow up with the site for any missing documents or clarifications
4. Submit the report for internal review and final decision-making

Common Red Flags During SQVs:

• Unavailable or disinterested PI
• Inadequate documentation or outdated certifications
• Limited access to IMP storage or lab facilities
• Poor inspection history or unresolved audit findings

Any red flags must be documented and addressed before final selection.

Best Practices for Successful SQVs:

1. Use standardized checklists aligned with SOPs
2. Include cross-functional team members when needed (QA, Regulatory)
3. Allow sufficient time for thorough facility walkthrough and Q&A
4. Summarize and review findings with the site before departure
5. Keep digital records of visit notes, photos, and signed attendance logs

Conclusion:

Site Qualification Visits are a foundational step in ensuring clinical trial success. By conducting structured, SOP-driven evaluations, sponsors can verify site readiness, minimize operational risks, and select the most capable investigators. Clear documentation, collaborative discussions, and follow-up are key to deriving maximum value from the SQV process. For tools and templates to streamline your SQVs, refer to resources at Stability Studies.